We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

QUIDEL

  Gold Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App





Quidel Showcases Comprehensive Suite of COVID-19 Testing Solutions at MEDLAB Middle East 2021

By LabMedica International staff writers
Posted on 21 Jun 2021
Print article
Image: Sofia Q Fluorescent Immunoassay Analyzer (Photo courtesy of Quidel Corporation)
Image: Sofia Q Fluorescent Immunoassay Analyzer (Photo courtesy of Quidel Corporation)
Quidel Corporation (San Diego, CA, USA) showcased its comprehensive suite of COVID-19 testing solutions at MEDLAB Middle East 2021 that took place in Dubai from 21-24 June.

Quidel introduced its new Sofia Q Fluorescent Immunoassay Analyzer, a powerful clinical diagnostic device in a very compact size, to be used with its Sofia SARS Antigen FIA Test Cassettes to diagnose COVID-19. Sofia Q uses advanced fluorescence detection with an ultraviolet LED energy source and collects hundreds of data points on the test strip contained inside the Test Cassette. Quidel recently received an amended Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition to the Sofia and Sofia 2 line of Fluorescent Immunoassay Analyzers (FIA).

In addition to the Sofia Q, Quidel also exhibited other rapid diagnostic instrumented systems, including Sofia 2, and Sofia. Also on display were Quidel’s Sofia assays for rapid antigen COVID-19 diagnosis, including Sofia 2 SARS Antigen FIA and Sofia 2 Flu + SARS Antigen FIA, currently under EUA by the FDA. At MEDLAB Middle East 2021, Quidel also highlighted its other FDA-cleared and CLIA-waived tests, including Influenza A and B, Respiratory Syncytial Virus (RSV), Group A Strep, and a 15-minute finger-stick whole blood test for Lyme Disease.

Related Links:
Quidel Corporation

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
Pipette Tips
Sapphire Pipette Tips
New
Blood Grouping Kit
ABO & RhD Blood Grouping Kit
New
Platinum Supplier
Hormonal Test
Endocrine Array

Print article

Channels

Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.